公开(公告)号：US20220133881A1

公开(公告)日：2022-05-05

申请号：US17576021

申请日：2022-01-14

申请人： SANOFI PASTEUR LIMITED ,  SANOFI PASTEUR BIOLOGICS, LLC

发明人： Stephen ANDERSON ,  Simon DELAGRAVE ,  John HAMBERGER ,  Qinglian LI ,  Sophia MUNDLE ,  Nausheen RAHMAN

IPC分类号： A61K39/245 ,  A61K39/12 ,  A61K47/26 ,  A61K47/18 ,  A61K9/00 ,  C12N7/00

摘要： The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compostions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.

公开(公告)号：US11260123B2

公开(公告)日：2022-03-01

申请号：US14402678

申请日：2013-05-21

申请人： SANOFI PASTEUR LIMITED ,  SANOFI PASTEUR BIOLOGICS, LLC

发明人： Stephen Anderson ,  Simon Delagrave ,  John Hamberger ,  Qinglian Li ,  Sophia Mundle ,  Nausheen Rahman

IPC分类号： A61K39/245 ,  A61K39/12 ,  A61K47/26 ,  A61K47/18 ,  A61K9/00 ,  C12N7/00 ,  A61K39/00

摘要： The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exctpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.

公开(公告)号：US20150150964A1

公开(公告)日：2015-06-04

申请号：US14402678

申请日：2013-05-21

申请人： SANOFI PASTEUR LIMITED ,  SANOFI PASTEUR BIOLOGICS, LLC

发明人： Stephen Anderson ,  Simon Delagrave ,  John Hamberger ,  Qinglian Li ,  Sophia Mundle ,  Nausheen Rahman

IPC分类号： A61K39/245 ,  C12N7/00

CPC分类号： A61K39/245 ,  A61K9/0019 ,  A61K39/12 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2710/16611 ,  C12N2710/16634 ,  C12N2710/16651

摘要： The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.

摘要翻译： 本公开涉及包含活的，减毒的或遗传修饰的疱疹病毒的液体和干燥的组合物以及制备这样的组合物的方法。一方面，组合物包含至少两种或更多种药学上可接受的优异剂，其中至少一种是组氨酸， 其中最少的一种是糖或糖醇。 组合物在储存或大规模制备步骤如冻干后保持足够高的感染滴度。

公开(公告)号：US20140255443A1

公开(公告)日：2014-09-11

申请号：US14097707

申请日：2013-12-05

申请人： Sanofi Pasteur Limited/Sanofi Pasteur Limitee

发明人： Lynn Doucette-Stamm ,  David Bush ,  Qiandong Zeng ,  Timothy Opperman ,  Chad Eric Houseweart

IPC分类号： C07K14/315

CPC分类号： C07K14/3156 ,  A61K31/7052 ,  A61K39/00 ,  A61K39/092 ,  A61K2039/53 ,  C07H21/02 ,  C07H21/04 ,  C07K14/315

摘要： The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection.

摘要翻译： 本发明提供了用与SEQ ID NO：5326具有至少80％同一性的多肽治疗受试者的方法。该方法刺激受试者的免疫应答并提供预防和治疗由细菌感染引起的病理状况的方法。

公开(公告)号：US20160367655A1

公开(公告)日：2016-12-22

申请号：US15075279

申请日：2016-03-21

申请人： Sanofi Pasteur Limited ,  Sanofi Pasteur, S.A.

发明人： Scott Gallichan ,  Ausra Mancevski ,  Nathalie Reveneau ,  Jin Su ,  Francois Dalencon ,  Jean Haensler

IPC分类号： A61K39/118 ,  A61K39/39

CPC分类号： A61K39/39 ,  A61K9/0019 ,  A61K9/107 ,  A61K9/1075 ,  A61K39/118 ,  A61K47/44 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/572 ,  A61K2039/575

摘要： The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.

摘要翻译： 本发明提供了包含来自至少一种衣原体血清型和佐剂的衣原体主要外膜蛋白（本文称为“MOMP”）的组合物，其特征在于所述佐剂包含具有CAS号287180-63-6的产物E6020。 该组合物还可以包含至少一种载体体系（例如乳液，矿物颗粒）。 MOMP蛋白可以衍生自衣原体（例如沙眼衣原体，沙眼衣原体，肺炎衣原体，鹦鹉热鹦鹉或C.沙眼衣原体MoPn）的任何种类。 在优选的实施方案中，组合物包含一种或多种主要的外膜蛋白，其各自衍生自沙眼衣原体的不同血清型。 本发明还提供了通过向受试者施用本发明的组合物来诱导受试者对衣原体（例如沙眼衣原体）的免疫应答的方法。

公开(公告)号：US12116402B2

公开(公告)日：2024-10-15

申请号：US17538731

申请日：2021-11-30

申请人： SANOFI PASTEUR INC.

发明人： Stephen F. Anderson ,  Natalie Anosova ,  Nicola Beltraminelli ,  Pierre Garrone ,  Harold Kleanthous ,  Majid Mehtali ,  Jianxin Zhang

IPC分类号： A61K39/40 ,  C07K16/12 ,  A61K39/00

CPC分类号： C07K16/1282 ,  A61K39/40 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

摘要： Monoclonal antibodies, or antigen-binding fragments thereof, that bind to Clostridium difficile (C. difficile) toxin A or toxin B and methods of using the same to detect or treat C. difficile infections and/or C. difficile-associated disease.

公开(公告)号：US20240277828A1

公开(公告)日：2024-08-22

申请号：US18653422

申请日：2024-05-02

申请人： SANOFI PASTEUR INC

发明人： Timothy ALEFANTIS ,  Mario BARRO ,  Anthony BYERS ,  Guadalupe CORTES-GARCIA ,  Philippe-Alexandre GILBERT ,  Harold KLEANTHOUS ,  Armaghan NAIK ,  Konstantin PUGACHEV ,  Saranya SRIDHAR ,  Thorsten VOGEL ,  William WARREN

IPC分类号： A61K39/145 ,  A61K39/00 ,  A61P37/04

CPC分类号： A61K39/145 ,  A61P37/04 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/70

摘要： Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.

公开(公告)号：US11931406B2

公开(公告)日：2024-03-19

申请号：US16772131

申请日：2018-12-12

申请人： CureVac SE ,  Sanofi Pasteur

发明人： Patrick Baumhof ,  Wolfgang Grosse ,  Edith Jasny ,  Thomas Kramps ,  Daniel Voss ,  Julia Dannenmaier ,  Valérie Lecouturier ,  Yves Girerd-Chambaz

IPC分类号： A61K39/12 ,  A61P31/14 ,  A61K39/00

CPC分类号： A61K39/12 ,  A61P31/14 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/6031 ,  C12N2770/24134

摘要： The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.

公开(公告)号：US11904012B2

公开(公告)日：2024-02-20

申请号：US17400390

申请日：2021-08-12

申请人： SANOFI PASTEUR INC.

发明人： Tod Strugnell ,  Eliud Oloo ,  Raymond Oomen

IPC分类号： C07K14/005 ,  C07K14/11 ,  C07K16/10 ,  C07K16/18 ,  A61K39/145 ,  A61P31/16 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/145 ,  A61P31/16 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5258 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134

摘要： The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.

公开(公告)号：US11827668B2

公开(公告)日：2023-11-28

申请号：US17813445

申请日：2022-07-19

申请人： SANOFI PASTEUR INC.

发明人： Tod Dwayne Strugnell ,  Guadalupe Cortes-Garcia ,  Tim Alefantis

IPC分类号： C07K14/11 ,  G01N33/569 ,  C07K14/005 ,  C07K16/10

CPC分类号： C07K14/11 ,  C07K14/005 ,  C07K16/10 ,  G01N33/569 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16222 ,  C12N2760/16234 ,  C12N2800/22

摘要： The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. Also provided are methods of preparing an influenza vaccine composition using the optimized nucleotide sequences, as well as methods of inducing an immune response using the influenza vaccine composition.